Valuation: Altimmune, Inc.

Market Cap 532M 473M 441M 402M 758M 51.23B 765M 5.34B 2.07B 26.13B 2B 1.95B 83.97B P/E 2026 *
-4.7x
P/E 2027 * -4.3x
Enterprise Value 91.51M 81.33M 75.81M 69.11M 130M 8.81B 132M 919M 356M 4.49B 344M 336M 14.44B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.58%
Yield 2026 *
-
Yield 2027 * -
1 day-0.91%
1 week-10.62%
Current month-4.37%
1 month-16.62%
3 months-13.45%
6 months-18.11%
Current year-24.24%
1 week 2.71
Extreme 2.71
3.07
1 month 2.71
Extreme 2.71
3.55
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap. Importance
16/9/26 Exercice

Executive/Senior Manager

54,826 0.0282%
13/8/26 Buy

Chief Executive Officer

15,000 0.0077%
31/7/26 Free

Chief Financial Officer

1,753 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-0.91%-10.62%-30.41%+7.68% 532M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.29%-1.59%+45.91%+109.02% 39.11B
Weighted average by Cap. +0.12%-0.85%+58.64%+129.74%

Financials

2026 *2027 *
Net sales - -
Net income -99.55M -88.48M -82.47M -75.18M -142M -9.59B -143M -1B -387M -4.89B -374M -366M -15.71B -117M -104M -96.75M -88.19M -166M -11.25B -168M -1.17B -455M -5.73B -438M -429M -18.43B
Net Debt -440M -392M -365M -333M -628M -42.42B -634M -4.42B -1.71B -21.63B -1.65B -1.62B -69.52B -332M -295M -275M -251M -473M -31.94B -477M -3.33B -1.29B -16.29B -1.25B -1.22B -52.35B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
02/10/26 USD 2.735 -0.91% 4,252,719
01/10/26 USD 2.760 -3.50% 3,593,558
30/09/26 USD 2.860 -3.70% 4,922,486
29/09/26 USD 2.970 +0.34% 2,563,649
28/09/26 USD 2.960 -3.27% 3,359,771
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.735USD
Average target price
17.11USD
Spread / Average Target
+525.63%

Quarterly revenue - Rate of surprise